▶ 21:40 · Healthcare Systems & Policy · US for-profit system enables price appreciation; EU public systems drive price erosion

episode briefing

Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable

2026-06-10 · 8 company · 10 thematic

sentiment

5 bull1 bear2 neu

speakers

pablo

Practitioner of the forward-deployed engineer model. Described how his team of 50 deployment engineers (growing to 75-100) acts as problem-solvers for enterprise clients, becoming the best sales channel.

yolanda pérez

Leads health tech investing for V Startup, Banco Sabadell's corporate venture arm, which has invested in ~23 health companies since 2017 across therapeutics, devices, digital health, and diagnostics; focuses on Spanish science spinouts needing early capital.

jesús monleón

Host of SeedRocket's 4Founders podcast; runs Go Trendier (a secondhand fashion marketplace) and 4Founders; actively applies AI learnings from guests to his own companies.

now playing · Healthcare Systems & Policy

AI Drug Discoverytailwindscore 8/10pablo

FDA accepts AI-powered synthetic control arms to accelerate clinical trials

The FDA now permits using historical patient data with AI to replace placebo arms in pivotal trials, cutting recruitment costs and time; EMA has not yet followed, creating a regulatory arbi…

Medical Imaging & Diagnosticstailwindscore 8/10pablo

Liquid biopsy detects cancer recurrence 16 months earlier but US adoption dwarfs Europe

Circulating tumor DNA assays provide 16-month lead time over imaging for breast cancer recurrence, enabling life decisions like pregnancy before treatment; US reimbursement drives 70% adopt…

Healthcare Systems & Policytailwindscore 8/10pablo

US for-profit system enables price appreciation; EU public systems drive price erosion

US healthcare's employer-insurer-provider incentives allow persistent price increases post-launch, while European single-payer systems systematically push drug/device prices down, making US…

AI Drug Discoverytailwindscore 7/10pablo

US health data access enables faster AI model training vs EU GDPR constraints

US portfolio companies train medical AI models years faster due to broader data interoperability and private-sector incentives, while EU's consensus-based approach delays data access and mo…

Brain-Computer Interfacestailwindscore 7/10yolanda pérez

Graphene-based neural interfaces achieve higher resolution than metallic electrodes

Inbrain's graphene chips enable superior signal fidelity and biocompatibility vs Neuralink's traditional electrodes, with human implants already restoring motor function in Parkinson's pati…

Enterprise AI Adoptionheadwindscore 7/10pablo

Digital health point solutions fail venture return thresholds; platforms win

Single-condition digital tools (e.g., maternity apps) hit revenue ceilings and deliver 3-5x returns over 9+ years — insufficient for VC — while integrated platforms combining telehealth, ph…

GLP-1 & Metabolic Drugstailwindscore 9/10pablo

Employer-paid diabetes reversal programs become mandatory step before GLP-1 coverage

Virta Health's model — reverse type 2 diabetes via lifestyle intervention paid by employers — is being inserted as a required gateway before expensive GLP-1 prescriptions, creating a high-m…

AI Drug Discoverytailwindscore 9/10pablo

mRNA manufacturing infrastructure is the picks-and-shovels play for 200+ therapeutic pipeline

With 200+ mRNA therapeutics in clinical trials but production methods unchanged since the 1970s — expensive, poor scaling, concentrated supply chain — investing in novel manufacturing platf…

Gene & Cell Therapytailwindscore 8/10pablo

Ex vivo organ perfusion enables treatment of organs outside the body before transplant

Bloodless perfusion solutions keep donor organs viable at body temperature, allowing drug treatment of organs ex vivo (e.g., reversing fatty liver) before reimplantation — a platform applic…

AI in Healthcareriskscore 6/10pablo

Preventive multi-marker testing lacks actionability without personalized intervention evidence

Blood tests predicting Alzheimer's or cancer risk 20 years out have limited clinical utility because evidence-based personalized prevention is lacking; insurers understand risk but won't pa…

←